Latest & greatest articles for nifedipine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nifedipine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nifedipine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nifedipine

21. Nifedipine: dose-related increase in mortality in patients with coronary heart disease

Nifedipine: dose-related increase in mortality in patients with coronary heart disease Nifedipine: dose-related increase in mortality in patients with coronary heart disease Nifedipine: dose-related increase in mortality in patients with coronary heart disease Furberg C D, Psaty B M, Meyer J V Authors' objectives To assess the effect of nifedipine dose on mortality and to review the potential mechanisms of such an effect. Searching The authors do not provide details of the sources searched (...) or the strategies used. Study selection Study designs of evaluations included in the review All published randomised controlled trials (RCTs) of nifedipine in the secondary prevention of CHD for which mortality data were available, were included. Specific interventions included in the review Nifedipine at doses of 30, 40, 50, 60, 80 and 100 mg/day, to a maximum of 120 mg. Participants included in the review Patients with coronary heart disease (CHD). Of the 16 studies included, 12 included patients

DARE.1995

22. Use of nifedipine in the hypertensive diseases of pregnancy

Use of nifedipine in the hypertensive diseases of pregnancy Use of nifedipine in the hypertensive diseases of pregnancy Use of nifedipine in the hypertensive diseases of pregnancy Levin A C, Doering P L, Hatton R C Authors' objectives To review available data about the use of nifedipine to treat hypertension in pregnancy. Searching MEDLINE, Excerpta Medica and BIOSIS Previews were searched from 1984 onwards for studies published in the English language, using the headings 'nifedipine (...) ', 'hypertension in pregnancy', 'uteroplacental blood flow', 'maternal/fetal hemodynamics', 'pre-eclampsia' and 'pregnancy outcome'. Study selection Study designs of evaluations included in the review The authors do not provide any details of the designs of the included studies. Specific interventions included in the review Acute administration of nifedipine, either alone or in conjunction with other blood-pressure medications including hydralazine, methyldopa, labetalol, atenolol, or methyldopa plus atenolol

DARE.1994

23. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function.

Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. 8058074 1994 09 15 1994 09 15 2013 11 21 0028-4793 331 11 1994 Sep 15 The New England journal of medicine N. Engl. J. Med. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. 689-94 Vasodilator therapy with nifedipine reduces left ventricular volume and mass and increases the ejection fraction in asymptomatic patients with severe (...) aortic regurgitation. To assess whether vasodilator therapy reduces or delays the need for valve replacement, we randomly assigned 143 asymptomatic patients with isolated, severe aortic regurgitation and normal left ventricular systolic function to receive either nifedipine (20 mg twice daily, 69 patients) or digoxin (0.25 mg daily, 74 patients). By actuarial analysis, we determined that after six years a mean (+/- SD) of 34 +/- 6 percent of the patients in the digoxin group had undergone valve

NEJM1994

24. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis.

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. 1458144 1993 01 13 1993 01 13 2013 11 21 0959-8138 305 6860 1992 Oct 24 BMJ (Clinical research ed.) BMJ Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. 981-5 To compare the efficacy, safety, and tolerance of enalapril and nifedipine in hypertensive patients with (...) non-insulin dependent diabetes. One year double blind follow up of patients randomly allocated to either enalapril or nifedipine with matching placebos for the alternative drug. Metabolic Investigation Unit, Hong Kong. 102 patients were randomised: 52 to nifedipine and 50 to enalapril. At baseline 44 patients had normoalbuminuria, 36 microalbuminuria, and 22 macroalbuminuria. Blood pressure, albuminuria, and parameters of renal function and glycaemic control. In patients who completed one year's treatment the median dose

BMJ1992 Full Text: Link to full Text with Trip Pro

25. beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination.

beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. 1747577 1992 01 21 1992 01 21 2013 11 21 0959-8138 303 6810 1991 Nov 02 BMJ (Clinical research ed.) BMJ beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. 1100-4 To determine the effects of the beta 1 selective adrenoceptor blocker atenolol, the dihydropyridine calcium antagonist nifedipine (...) , and the combination of atenolol plus nifedipine on objective and subjective measures of walking performance and foot temperature in patients with intermittent claudication. Randomised controlled double blind four way crossover trial. Royal Hallamshire Hospital, Sheffield. 49 patients (40 men) aged 39-70 with chronic stable intermittent claudication. Atenolol 50 mg twice daily; slow release nifedipine 20 mg twice daily; atenolol 50 mg plus slow release nifedipine 20 mg twice daily; placebo. Each treatment

BMJ1991 Full Text: Link to full Text with Trip Pro

26. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina.

Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. 1681355 1991 11 21 1991 11 21 2016 11 23 0140-6736 338 8774 1991 Oct 26 Lancet (London, England) Lancet Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. 1036-9 Many patients with angina pectoris whose symptoms are not completely controlled by beta-blockers are treated with several types of drugs, but it is not clear whether addition of a calcium (...) -channel antagonist and/or a nitrate confers any advantage over beta-blockade alone. 18 patients receiving atenolol for stable angina pectoris completed a double-blind, randomised, crossover trial of atenolol treatment plus placebo, isosorbide mononitrate, nifedipine, and mononitrate and nifedipine (triple therapy). The patients were assessed subjectively and by treadmill exercise testing and 24 h ambulatory electrocardiographic recordings at the end of each 4-week treatment period. There were

Lancet1991

27. Prevention of high-altitude pulmonary edema by nifedipine.

Prevention of high-altitude pulmonary edema by nifedipine. 1922223 1991 11 05 1991 11 05 2013 11 21 0028-4793 325 18 1991 Oct 31 The New England journal of medicine N. Engl. J. Med. Prevention of high-altitude pulmonary edema by nifedipine. 1284-9 Exaggerated pulmonary-artery pressure due to hypoxic vasoconstriction is considered an important pathogenetic factor in high-altitude pulmonary edema. We previously found that nifedipine lowered pulmonary-artery pressure and improved exercise (...) performance, gas exchange, and the radiographic manifestations of disease in patients with high-altitude pulmonary edema. We therefore hypothesized that the prophylactic administration of nifedipine would prevent its recurrence. Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly

NEJM1991

28. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group.

Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. 1998761 1991 04 05 1991 04 05 2013 11 21 0959-8138 302 6770 1991 Jan 26 BMJ (Clinical research ed.) BMJ Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Melbourne Diabetic Nephropathy Study Group. 210-6 To compare the efficacy of angiotensin converting enzyme (...) inhibition with calcium antagonism in diabetic patients with microalbuminuria. Randomised study of diabetic patients with microalbuminuria treated with perindopril or nifedipine for 12 months and monitored for one or three months after stopping treatment depending on whether they were hypertensive or normotensive. Patients were randomised separately according to whether they were hypertensive or normotensive. Diabetic clinics in three university teaching hospitals. 50 diabetic patients with persistent

BMJ1991 Full Text: Link to full Text with Trip Pro

29. Interaction of citrus juices with felodipine and nifedipine.

Interaction of citrus juices with felodipine and nifedipine. 1671113 1991 02 22 1991 02 22 2015 06 16 0140-6736 337 8736 1991 Feb 02 Lancet (London, England) Lancet Interaction of citrus juices with felodipine and nifedipine. 268-9 Six men with borderline hypertension took felodipine 5 mg with water, grapefruit juice, or orange juice. The mean felodipine bioavailability with grapefruit juice was 284 (range 164-469)% of that with water. The dehydrofelodipine/felodipine AUC ratio was lower (...) , diastolic blood pressure lower, and heart rate higher with grapefruit juice than with water. Vasodilatation-related side-effects were more frequent. Orange juice had no such effects. Six healthy men took nifedipine 10 mg with water or grapefruit juice; the bioavailability with grapefruit juice was 134 (108-169)% of that with water. Bailey D G DG Department of Medicine, Victoria Hospital, University of Western Ontario, London, Canada. Spence J D JD Munoz C C Arnold J M JM eng Clinical Trial Journal

Lancet1991

30. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.

Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. 1971861 1990 07 09 1990 07 09 2016 11 23 0140-6736 335 8698 1990 May 12 Lancet (London, England) Lancet Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators (...) . 1109-13 425 patients showing mild coronary artery disease (CAD) on arteriography were enrolled in a multicentre trial and randomised to treatment with nifedipine (80 mg/day) or placebo. The two groups were well matched for age, sex, and risk factors. 348 patients (82%) underwent repeat arteriography 3 years later; 282 (134 nifedipine, 148 placebo) had received treatment throughout, but treatment had been stopped in 39 nifedipine-treated and 27 placebo-treated patients after average periods of 354

Lancet1990

31. Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure.

Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure. 2146983 1991 01 03 1991 01 03 2013 11 21 0959-8138 301 6752 1990 Sep 22 BMJ (Clinical research ed.) BMJ Long term reduction in sodium balance: possible additional mechanism whereby nifedipine lowers blood pressure. 580-4 To assess the changes in sodium excretion and sodium balance after withdrawal of long term nifedipine. Single blind, placebo controlled study in patients receiving (...) fixed sodium and potassium intakes. Blood pressure unit of a teaching hospital in south London. Eight patients with mild to moderate uncomplicated essential hypertension who had been taking nifedipine 20 mg twice daily for at least six weeks. Withdrawal of nifedipine and replacement with matching placebo for one week. Urinary sodium excretion and cumulative sodium balance, body weight, plasma atrial natriuretic peptide concentrations, plasma renin activity and aldosterone concentrations, and blood

BMJ1990 Full Text: Link to full Text with Trip Pro

32. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. 2467711 1989 05 15 1989 05 15 2013 11 21 0959-8138 298 6673 1989 Mar 04 BMJ (Clinical research ed.) BMJ Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. 561-4 To compare the long term effects (...) of short term intravenous infusions of iloprost with those of oral nifedipine in patients with Raynaud's phenomenon associated with systemic sclerosis. Double blind, placebo controlled, randomised group comparison. Dermatology outpatient clinic. Twenty three patients with Raynaud's phenomenon associated with well documented systemic sclerosis (American Rheumatism Association criteria) and with typical abnormalities in fingernail folds on capillaroscopy. Twelve patients were randomised to receive

BMJ1989 Full Text: Link to full Text with Trip Pro

33. Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions.

Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions. 6471300 1984 10 25 1984 10 25 2016 10 17 0098-7484 252 13 1984 Oct 05 JAMA JAMA Effects of nifedipine in achalasia and in patients with high-amplitude peristaltic esophageal contractions. 1733-6 We studied the esophageal effects of nifedipine in 20 patients with achalasia (20 mg sublingually) and nine patients with high-amplitude peristaltic esophageal contractions (nutcracker esophagus (...) ) (20 mg orally). In patients with achalasia, nifedipine decreased lower esophageal sphincter (LES) pressure by approximately 30%. In ten patients with achalasia, plasma nifedipine concentrations were 45.3 +/- 17.7 and 57.4 +/- 12.8 ng/mL (means +/- SEM) at 30 and 60 minutes, respectively, after drug administration. In patients with nutcracker esophagus, nifedipine decreased LES pressure by approximately 50% and contraction amplitude in the body of the esophagus by approximately 25%. After

JAMA1984

34. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine.

Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. 6366561 1984 04 26 1984 04 26 2013 11 21 0028-4793 310 15 1984 Apr 12 The New England journal of medicine N. Engl. J. Med. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. 951-4 To determine whether cigarette smoking affects the results of drug treatment for angina, we studied 10 cigarette smokers with angina who were given placebo, nifedipine (60 mg per day (...) the nonsmoking phase of the study, there was an overall decline in the frequency of angina and an improvement in performance on exercise testing (P less than 0.05) as compared with the smoking period, although the results of 48-hour ambulatory monitoring remained unchanged. The improvement after patients stopped smoking was greater during treatment with nifedipine than during administration of the other two drugs or placebo. Blood levels of propranolol were increased when patients stopped smoking; levels

NEJM1984

35. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.

Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. 6128596 1983 01 19 1983 01 19 2015 06 16 0140-6736 2 8311 1982 Dec 11 Lancet (London, England) Lancet Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. 1299-301 17 patients with moderate to severe Raynaud's phenomenon were entered into a 6 week randomised double-blind crossover study to compare the efficacy of nifedipine with that of placebo. Nifedipine significantly reduced the frequency of attacks (...) and also the severity of attacks, which was assessed by the patients on a linear analogue scale. Patients gave nifedipine a significantly higher drug-effectiveness score than placebo. Skin temperature recovery times were not affected by treatment with nifedipine. 12 of the patients regarded nifedipine as effective in reducing the frequency and severity of Raynaud's phenomenon. Smith C D CD McKendry R J RJ eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Lancet1982

36. Nifedipine in unstable angina: a double-blind, randomized trial.

Nifedipine in unstable angina: a double-blind, randomized trial. 7038491 1982 05 21 1982 05 21 2013 11 21 0028-4793 306 15 1982 Apr 15 The New England journal of medicine N. Engl. J. Med. Nifedipine in unstable angina: a double-blind, randomized trial. 885-9 We assessed the efficacy of adding nifedipine to the conventional treatment of unstable angina in 138 patients in a prospective, double-blind, randomized, placebo-controlled trial. There was no difference between the two groups in the dose (...) of conventional antianginal medication or in age, prior myocardial infarction, ejection fraction, or other risk factors. Failure of medical treatment (defined as sudden death, myocardial infarction, or bypass surgery within four months) occurred in 43 of 70 patients given placebo and in 30 of 68 given nifedipine. Kaplan-Meier survival-curve analysis of the number and time dependence of treatment failures demonstrated a benefit of nifedipine over placebo (P = 0.03). The benefit was particularly marked

NEJM1982